France's Sanofi Q2 revenue rises 17.8%, beats estimates

Sanofi SA

30/07/2026 06:41

Overview
French pharmaceuticals firm's Q2 revenue rose 17.8% at constant exchange rates (CER), beating analyst expectations
Business EPS for Q2 grew 33.3% at CER
Company upgraded 2026 guidance, now sees sales up ~10% at CER

Outlook
Sanofi expects 2026 sales to grow by around 10% at CER
Company sees 2026 business EPS growing slightly faster than sales at CER
Sanofi projects Dupixent sales to reach €25 bln in 2030 at CER

Result Drivers
PHARMA LAUNCHES - Co said 48.3% growth in sales from new pharmaceutical launches, mainly Ayvakit, ALTUVIIIO, and Sarclisa, drove results
DUPIXENT GROWTH - Dupixent sales rose 37.6% to €5.2 bln, surpassing €5 bln per quarter for the first time
VACCINES DECLINE - Vaccines sales fell 4.7% to €1.1 bln, impacted by a high basis of comparison in influenza vaccines

Company press release: ID:nGNX7DlpxQ

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
EUR 11.60 bln
EUR 11.22 bln (7 Analysts)
Q2 EPS
 
EUR 0.29
 
Q2 Net Income
 
EUR 343 mln
 
Q2 Free Cash Flow
 
EUR 2.67 bln
 
Q2 Operating Income
 
EUR 3.29 bln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 11 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Sanofi SA is €95.00, about 18.9% above its July 29 closing price of €79.92
The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 10 three months ago

Reuters Recommended Reads
July 30 - Sanofi raises sales outlook on Dupixent strength in boost for new CEO
July 30 - France's Ipsen H1 revenue rises 20.4%, lifts 2026 outlook
July 28 - GSK raises margin outlook, plots $2.5 billion restructuring to fast-track new drugs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)